



## ASX ANNOUNCEMENT

### Investor Information Sessions

**MELBOURNE, Australia (31 January 2024)** – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to invite shareholders and potential investors to attend in-person presentations in Melbourne or Sydney.

Lumos CEO, Doug Ward and CFO, Barrie Lambert will provide an update on the business, including the opportunities ahead, following the recent Hologic announcement, and will discuss the commercialisation progress on FebriDx and ViraDx products. The presentations will be followed by a Q&A session. After the conclusion of the session, participants are invited to join the Lumos team for refreshments.

Registration details for these events can be found below.

#### IN-PERSON BRIEFING OPTIONS FOR INVESTORS

To register, please click the location-specific link below, then enter your name and contact details. <b>Please register by close of business this coming Friday, 2 February 2024.</b>	
<b>Melbourne</b>	<b>Monday, 5 February 2024, 11.45am arrival for 12pm-2pm</b> William Buck, Level 20, 181 William Street, Melbourne. Light lunch provided. Register: <a href="#">Investor briefing - Melbourne</a>
<b>Sydney</b>	<b>Thursday, 8 February 2024, 12pm arrival for 12:15pm-1.45pm</b> State Library of NSW – Macquarie Room, 1 Shakespeare Place (enter via Macquarie St), Sydney. Light lunch provided. Register: <a href="#">Investor briefing - Sydney</a>

The Lumos investor relations team looks forward to welcoming those shareholders and potential investors who are able to attend.

-Ends-

For personal use only

***This announcement has been approved by the Lumos Company Secretary.***

**About Lumos Diagnostics**

*Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).*

**Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

**Media Contact:**

Haley Chartres – Australia  
HACK Director  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 (0) 423 139 163

**Investor Contact:**

Jane Lowe  
Managing Director, IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 411 117 774

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205, Australia  
+61 3 9087 1598

For personal use only